Ivantis Hits 2 Major Milestones for its Minimally Invasive Glaucoma Surgery (MIGS)

08 January 2018

In October, Ivantis completed its pre-market approval for Hydrus Microstent, its Minimally Invasive Glaucoma Surgery procedure. Dave Van Meter, president and CEO of Ivantis, elaborates further on the importance of this milestone: “The submission of Ivantis’ PMA marks a significant milestone toward our goal of bringing the Hydrus Microstent to market in the United States […]

Continue Reading

Vertex Venture Holdings gets funds to go global

05 October 2015

Armed with a war chest of US$600 million (S$857 million), Singapore’s largest and oldest venture capital firm is going global. The infusion of cash will allow Vertex Venture Holdings to invest in start-ups in the hot seats of innovation and technological disruption – United States, Israel and China – after having been mainly focused on […]

Continue Reading

Andrew Luck a NFL legend in the making

10 January 2015

Sooner than it gets lost and, Without a doubt, How can you ever overlook a 28 point comeback win in a playoff game, Regardless? In what will be next, It time to reflect on what Andrew Luck has been able to do in less than two years in a town Peyton Manning used to own. […]

Continue Reading

Visterra Closes $30 Million Series B Financing – Co-led by New Investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek

02 October 2014

Cambridge, MA – October 2, 2014 Visterra, Inc., a biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, today announced that it has completed a $30 million Series B financing round. The proceeds will be used to advance the development of multiple product candidates from the company’s […]

Continue Reading